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A B S T R A C T
Sumatriptan, a 5HT (5-hydroxytryptamine)1B/1D receptor agonist, showed neuroprotection in diﬀerent studies.
The aim of the present study was to investigate the eﬀect of sumatriptan on morphine-induced antinociceptive
tolerance and physical dependence. We also investigated the possible role of nitric oxide (NO) on sumatriptan
eﬀects.
Tolerance was induced by morphine injection (50, 50, 75mg/kg) three times daily for ﬁve days.
Antinociceptive latency after acute and chronic treatment with sumatriptan (0.001, 0.01, 0.1 and 1mg/kg) was
measured by hot plate test in morphine-dependent animals. To investigate the possible involvement of NO,
diﬀerent isoforms of nitric oxide synthase (NOS) inhibitors including L-NAME, aminoguanidine and 7-ni-
troindazole were co-administered with sumatriptan. Nitrite level in mice hippocampus was quantiﬁed by Griess
method. To examine the role of sumatriptan on physical dependence, three parameters of withdrawal signs were
recorded after injection of naloxone (4mg/kg).
Acute treatment with sumatriptan (0.01, 0.1 and 1mg/kg) attenuated the antinociceptive tolerance
(P < 0.001). Chronic injection of sumatriptan (0.001, 0.01 and 0.1 mg/kg), as well, decreased the anti-
nociceptive tolerance (P < 0.001). Moreover, co-administration of NOS inhibitors prevented the eﬀects of su-
matriptan. Sumatriptan signiﬁcantly increased the level of nitrite only after chronic administration. Sumatriptan
administration showed no alteration in naloxone-precipitated withdrawal signs.
Acute and chronic administration of sumatriptan attenuated morphine antinociceptive tolerance; at least in
chronic phase via nitrergic pathway. Our data did not support beneﬁcial eﬀects of sumatriptan on morphine-
induced physical dependence in mice.
1. Introduction
The long-term administration of morphine and related opioids re-
mains limited in pain management due to its adverse eﬀects such as
tolerance and dependence phenomena (Mao et al., 1995; Trujillo and
Akil, 1991). Tolerance occurs when the eﬃcacy of drug diminishes by
continued usage; therefore, dose increasing is required to maintain the
same therapeutic eﬀect. Dependence consists of psychological and
physical components. Psychological dependence is an obsessive need
for seeking the drug while physical part develops when drug cessation
causes withdrawal signs (Bläsig et al., 1973; Way et al., 1969).
To obtain a solution to prevent these two issues, it's essential to
study the probable mechanisms involved in morphine-induced toler-
ance and dependence. Among all the studies investigated the
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mechanisms contributed to opioid-induced tolerance and dependence,
the majority of evidence veriﬁed the involvement of nitric oxide (NO)
pathway (Herman et al., 1995; Mao, 1999; Marek et al., 1991; Nestler,
2004).
Sumatriptan, a selective 5HT1B/1D receptor agonist, is a well-known
drug for treatment of migraine and cluster headache. It's a well-toler-
ated drug with minor, rare and transient adverse eﬀects (Dechant and
Clissold, 1992; Ikeda et al., 2002). Although the mechanisms of action
of sumatriptan need to be clariﬁed, growing body of evidence presumed
NO-dependent pathway as one of the probable mechanisms involved in
its beneﬁcial eﬀects. Sumatriptan protective eﬀects are mediated by
inhibition of NO-induced calcium gene-related peptide (CGRP) synth-
esis, altering the balance of NO and superoxide in brain, and mod-
ulating the bioavailability of NO in central nervous system (CNS)
(Dechant and Clissold, 1992; Ikeda et al., 2002; Stepień et al., 1999).
Nitric oxide, which is derived from amino acid L-arginine by the
enzyme nitric oxide synthase (NOS), is an essential agent to produce
cyclic guanosine monophosphate (cGMP). There are three identiﬁed
isoforms of NOS, including inducible (iNOS), neuronal (nNOS) and
endothelial (eNOS), expressed in diﬀerent organs (Förstermann and
Sessa, 2011). Nitric oxide plays an important role in numerous phy-
siological and pathological conditions of CNS (Buisson et al., 1993;
Montague et al., 1994; Szabó, 1996). A great body of evidence sup-
ported the involvement of NO/cGMP pathway on the morphine-in-
duced tolerance and dependence. It has been shown that the suppres-
sion of NO by NOS inhibitors could suppress both the tolerance to
morphine-induced antinociception and the withdrawal symptoms in-
duced by naloxone (Babey et al., 1994; Elliott et al., 1994; Homayoun
et al., 2003; Mao et al., 1995).
The purpose of our study was to test the hypothesis of sumatriptan
eﬀects on the morphine-induced antinociceptive tolerance and physical
dependence in mice. We also examined the involvement of NO pathway
in the possible eﬀects of sumatriptan.
2. Materials and methods
2.1. Animals
The experiment was carried out on male NMRI mice (Naval Medical
Research Institute), 6–7 weeks old, weighing 25–30 g. Animals were
housed in cages under standard laboratory conditions (12-h light/dark
cycle with an average temperature of 22 ± 2 °C and humidity of
55 ± 2%) with free access to food and tap water except for the time of
experimental procedures. Each experimental group consists of 6–8 mice
and each mouse was used once during the study. All the experiments
were performed at the same time of every day. All procedures were
conducted in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals (NIH Publications No. 8023,
revised 1978) with the approval of Research and Medical Ethics
Committees of Tehran University of Medical Science. The study consists
of diﬀerent experimental groups as follows: group 1: morphine alone,
groups 2–5: acutely received four diﬀerent doses of sumatriptan, groups
6–9: chronically received four diﬀerent doses of sumatriptan, groups
10–13: morphine+ four diﬀerent acute doses of sumatriptan, groups
14–16: morphine+ sumatriptan+ three diﬀerent isoforms of acute
NOS inhibitors, groups 17–20: morphine+ four diﬀerent doses of
chronic sumatriptan, groups 21–23: morphine+ sumatriptan+ three
isoforms of chronic NOS inhibitors, groups 24–27: morphine+ acute
sumatriptan+ naloxone, groups 28–31: morphine+ chronic suma-
triptan+ naloxone.
2.2. Chemicals
The drugs that were used throughout this study were: sumatriptan, a
5HT1B/1D receptor agonist; morphine sulfate, an opioid receptor ago-
nist; L-NAME [L-NG-Nitro-L-arginine methyl ester hydrochloride], a
non-speciﬁc inhibitor of NOS; aminoguanidine, a selective inhibitor of
iNOS; 7-NI [7-nitroindazole], a selective inhibitor of nNOS; naloxone
hydrochloride, an opioids receptor antagonist. Drugs were administered
intraperitoneally (i.p.) in the volume of 10ml/kg of mouse body
weight. All drugs were dissolved in normal saline (NaCl 0.9%) freshly
for use except for 7-NI which was dissolved in a 1% aqueous solution of
dimethyl sulfoxide (DMSO), followed by sonication. Morphine sulfate
was purchased from TEMAD, IRAN, naloxone was provided from Tolid
Daru, Co Ltd, Tehran Iran, and all other drugs were purchased from
Sigma, USA.
2.3. Induction of antinociceptive tolerance and dependence to morphine
The experiment was performed to assess two main problems of
continued usage of morphine including tolerance and dependence. To
induce antinociceptive tolerance, multiple injections of morphine were
administered three times daily for 4 consecutive days with the doses of
50mg/kg (8:00 a.m.), 50mg/kg (11:00 a.m.) and 75mg/kg (4:00 p.m.)
(the third dose was higher in order to prevent withdrawal signs during
night). On the last day of each experiment (5th day), animals received a
single dose of morphine (50mg/kg). The protocol for induction of an-
tinociceptive tolerance to morphine was based on previous studies
(Javadi et al., 2013). To assess antinociceptive threshold and degree of
tolerance hot plate test was conducted.
The method of utilizing hot plate test for evaluating antinociceptive
property was ﬁrstly described by Eddy and Leimbach (Eddy and
Leimbach, 1953). The device consists of an electrically heated surface
(50 ± 2 °C) covered with a plexiglass tube (18 cm high × 22 cm dia-
meter) (Tahghigh-Gostaran-Teb, Iran). The antinociceptive threshold
was deﬁned as a time interval (s) between placing the animal on the
heated surface and pain response (licking the hind paw or jumping with
all four feet). Antinociceptive eﬀect of morphine was assessed 60min
after the ﬁrst injection of morphine on ﬁrst, third and ﬁfth days of the
experiment. If the animals could not respond within 90 s, they were
removed from the hot plate to prevent tissue damage. The increase in a
time of animal response considered as antinociceptive induction and
the decrease of antinociceptive threshold was determined as the degree
of tolerance.
In aim of rendering physical dependence, morphine was injected
three times daily with doses of 50 mg/kg (8:00 a.m.), 50mg/kg
(11:00 a.m.) and 75mg/kg (4:00 p.m.) (the higher dose was adminis-
tered to prevent withdrawal signs overnight) for 4 days and a single
dose of 100mg/kg on the last day of the study (ﬁfth day).
To induce withdrawal signs, naloxone (4mg/kg, i.p.) was ad-
ministered one h after the last dose of morphine (100mg/kg). After
naloxone injection, each animal was placed in separated plexiglass
cylinder (40 cm long, 25 cm wide and 45 cm high). Animals were ob-
served for one h, and signs of withdrawal including jumping and
rearing were recorded throughout this time. Percentage of weight loss
as another sign of withdrawal was determined by measuring animal's
weight before and 60min after naloxone injection.
2.4. Assessing the eﬀect of sumatriptan on morphine antinociceptive
tolerance and naloxone-induced withdrawal signs
To investigate the antinociceptive property of sumatriptan, these
doses of the drug were administrated alone (acute and chronic with
four doses of 0.001, 0.01, 0.1 and 1mg/kg) without morphine injection
45min before hot plate test.
We evaluated the eﬀect of sumatriptan on morphine-induced anti-
nociceptive tolerance based on two protocols: In the ﬁrst protocol,
diﬀerent doses of sumatriptan (0.001, 0.01, 0.1 and 1mg/kg) were
injected 45min only before the last dose of morphine on the last day of
the experiment in order to evaluate the acute treatment with suma-
triptan on morphine antinociceptive tolerance.
In the second protocol, four diﬀerent doses of sumatriptan (0.001,
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0.01, 0.1 and 1mg/kg) were administered 45min prior to injection of
every dose of morphine three times daily for 5 days. To assess the eﬀect
of sumatriptan on antinociceptive tolerance hot plate test was per-
formed on ﬁrst, third and ﬁfth days of the study.
In order to determine the role of sumatriptan in morphine physical
dependence and naloxone-induced withdrawal signs, various doses of
sumatriptan (0.001, 0.01, 0.1 and 1mg/kg) were administered in two
diﬀerent protocols similar to the method that was described previously
for the eﬀect of sumatriptan on antinociceptive tolerance.
To evaluate the eﬀect of acute and chronic doses of sumatriptan on
morphine dependence, naloxone precipitated withdrawal manifesta-
tions including jumping, rearing, and percentage of weight loss were
determined 45min after injection of morphine and immediately after
naloxone injection on the last day.
2.5. Assessing the antinociceptive latency in the sumatriptan-treated group
after the intervention of NOS inhibitors administration
To assess the role of NO on eﬀects of acute treatment with suma-
triptan, a single dose of 7-NI (40mg/kg), L-NAME (5mg/kg) and
aminoguanidine (100mg/kg) were administered only on the ﬁfth day
45min before the single injection of sumatriptan. To determine the role
of NO pathway on modulating eﬀect of chronic injection of suma-
triptan, NOS inhibitors including 7-NI (15mg/kg), L-NAME (2mg/kg),
aminoguanidine (50mg/kg) were administered 45min before every
dose of sumatriptan (90min before morphine administration) during
ﬁve days of experiment. Hot plate test was performed 45min after
morphine administration both in acute and chronic phases. We selected
sub-eﬀective doses of NOS inhibitors based on our previous study
(Hassanipour et al., 2016b).
2.6. Nitrite level assay in mice hippocampus
Rapid oxidation of NO leads to nitrite production. Mice of each
study group were selected to measure nitrite in their hippocampus.
Nitrite level was assessed by Griess reaction (Tsikas, 2007), brieﬂy,
frozen hippocampi were homogenized by addition of lysis buﬀer solu-
tion (pH=8, with an amount of 4–6 times of tissue sample weight),
homogenized samples then incubated at room temperature
(20 ± 10 °C) for ten min followed by centrifugation (13,400 RCF) for
15min. Supernatants obtained from centrifugation were assessed for
nitrite level assay.
2.7. Data analysis
The results are expressed as mean ± standard error of the mean
(S.E.M.). To perform the analysis, GraphPad Prism data analysis pro-
gram version 6 was used (GraphPad Software San Diego, CA, USA).
Diﬀerences within experimental groups were analyzed using one-way
analysis of variance (ANOVA) followed by Tukey's multiple compar-
isons and two-way ANOVA followed by Bonferroni post hoc test. P
value < 0.05 was considered signiﬁcant for all analyses.
3. Results
The summarized result of all behavioral studies is presented in
Table 1.
3.1. Induction of morphine antinociceptive tolerance
Fig. 1 shows the antinociceptive tolerance to morphine. Adminis-
tration of morphine during 5 days (three times daily for 4 consecutive
days with the doses of 50mg/kg, 50 mg/kg, and 75mg/kg; and a single
dose of 50mg/kg on 5th day) leads to the development of tolerance
which was assessed by hot plate test. The result revealed that anti-
nociceptive latency on the ﬁfth day is signiﬁcantly lower than the
latencies of the ﬁrst and third days and near to the antinociceptive
threshold of the control group (P < 0.001).
3.2. Assessment of the antinociceptive eﬀect of sumatriptan
Antinociceptive latency after both acute and chronic administration
of sumatriptan at doses of 0.001, 0.01, 0.1 and 1mg/kg was compared
to the control group which only received saline. As illustrated in the
Fig. 2 antinociception threshold after acute and chronic injection of
sumatriptan did not alter signiﬁcantly in comparison with the control
group but it was signiﬁcantly lower than the antinociceptive latency in
morphine-treated animals (P < 0.001).
3.3. Evaluation of the eﬀect of acute administration of sumatriptan on
morphine-induced antinociceptive tolerance
The eﬀect of acute administration of sumatriptan on morphine-in-
duced antinociceptive tolerance was assessed at diﬀerent doses (0.001,
0.01, 0.1 and 1mg/kg). The results showed that sumatriptan with doses
of 0.01, 0.1 and 1mg/kg markedly increased the antinociceptive
threshold compared to morphine-treated group (P < 0.001; Fig. 3).
However, the acute administration of sumatriptan (0.001mg/kg) did
not alter the morphine-induced antinociceptive tolerance in mice.
3.4. Role of NOS inhibitors in the eﬀects of acute administration of
sumatriptan on the morphine-induced antinociceptive tolerance
Fig. 4 shows the modulating role of NO on the eﬀects of acute
treatment with sumatriptan on morphine-induced antinociceptive tol-
erance. NOS inhibitors including L-NAME, a non-speciﬁc NOS inhibitor
(5 mg/kg), 7-NI, a speciﬁc nNOS inhibitor (40mg/kg), and aminogua-
nidine, a speciﬁc iNOS inhibitor (100mg/kg), were administered
45min before sumatriptan injection. Co-treatment with all types of NOS
inhibitors reversed the eﬀect of sumatriptan on the antinociceptive
tolerance. As demonstrated in Fig. 4, antinociceptive latency has been
alleviated signiﬁcantly via administration of NOS inhibitors in com-
parison to the sumatriptan plus morphine-treated group which did not
receive NOS inhibitors.
3.5. Eﬀect of chronic administration of sumatriptan on morphine
antinociceptive tolerance
As shown in Fig. 5, it is revealed that pain threshold in animals
which were chronically treated with morphine and sumatriptan (0.1
and 0.001mg/kg) was enhanced signiﬁcantly in comparison with
morphine-treated group (P < 0.001) on the last day of the experiment.
Moreover, chronic administration of sumatriptan at 0.01mg/kg in-
hibited the antinociceptive tolerance eﬀect compared to morphine
group (P < 0.01) on the ﬁfth day. Co-treatment of morphine and su-
matriptan at 1mg/kg showed no signiﬁcant eﬀect on antinociceptive
tolerance in comparison with animals which were treated only with
morphine.
3.6. Eﬀect of NOS inhibitors in chronic administration of sumatriptan on
the antinociceptive tolerance induced by morphine
Fig. 6 illustrates the involvement of NO on the eﬀect of sumatriptan
on morphine-induced antinociceptive tolerance. Three of NOS in-
hibitors including L-NAME (2mg/kg), 7-NI (15mg/kg) and amino-
guanidine (50mg/kg) were injected 45min before every injection of
sumatriptan (0.1 mg/kg) for ﬁve days. The results revealed that 7-NI
signiﬁcantly decreased the antinociceptive latency in comparison to the
sumatriptan-treated group (P < 0.01). Moreover, as it has been shown
in Fig. 6, chronic co-administration of sumatriptan with L-NAME and
aminoguanidine completely blocked the eﬀect of sumatriptan
(P < 0.05).
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Table 1
The eﬀects of sumatriptan (SUMA) administration on morphine (MOR)-induced antinociceptive tolerance and physical dependence. In expression phase sumatriptan
was injected only at the last day of experiment (5th day) and in induction phase sumatriptan was co-administered with morphine three times daily for 5 days. The
role of nitric oxide (NO) was investigated by administration of NO modulators (L-NAME, aminoguanidine, and 7-NI) in both induction and expression phases. n:
number of mice in each experimental group.
Experiments Drugs
Saline MOR SUMA (0.001, 0.01,
0.1, 1mg/kg)
MOR+SUMA (0.001, 0.01, 0.1, 1mg/kg) MOR+SUMA 0.1mg/kg+NO
modulators
Tolerance (expression) No eﬀect
n=8
↓Antinociception n=8 No eﬀect Each group
n=8
↑Antinociception (0.01,0.1, and 1mg/kg
SUMA) Each group n=8
↓Antinociception n=8
Tolerance (induction) No eﬀect
n=8
↓Antinociception n=8 No eﬀect Each group
n=8
↑Antinociception (0.01,0.1, and 1mg/kg
SUMA) Each group n=8
↓Antinociception Each group
n=8
Dependence
(expression)
No eﬀect
n=8
↑Dependence n=8 – No eﬀect n=8 –
Dependence
(induction)
No eﬀect
n=8
↑Dependence n=8 – No eﬀect n=8 –
Day
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Fig. 1. Induction of antinociceptive tolerance to morphine (MOR). Morphine
was administered three times daily for ﬁve consecutive days. Data are expressed
as mean± S.E.M. (n= 8). * ** P < 0.001 compared to the control group.
### P < 0.001 compared to the antinociceptive latency of the ﬁrst day of the
experiment.
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Fig. 2. Evaluation of the antinociceptive property of sumatriptan (SUMA) without co-administration of morphine (MOR). A. Acute injection of diﬀerent doses of
sumatriptan. B. Diﬀerent doses of sumatriptan were administered three times daily for ﬁve days. Data are expressed as mean ± S.E.M. (n=8). ***P < 0.001
compared to the control group.
Hot plate test
La
te
nc
y 
(s
ec
)
MO
R d
ay
 5
SU
MA
 0.
00
1
SU
MA
 0.
01
SU
MA
 0.
1
SU
MA
 1
0
20
40
60
80
100
******
***
Fig. 3. The eﬀect of acute injection of diﬀerent doses of sumatriptan (SUMA) on
morphine-induced antinociceptive tolerance. The sumatriptan doses were in-
jected 45min before the last dose of morphine (MOR) on the last day. Data are
expressed as mean ± S.E.M. (n= 8). ***P < 0.001 compared to the mor-
phine-treated group.
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3.7. Assessing the role of acute injection of sumatriptan on the naloxone-
induced withdrawal signs and physical dependence to morphine
As illustrated in Fig. 7, naloxone injection in animals under chronic
administration of morphine resulted in signiﬁcant increase in with-
drawal parameters including number of jumping, rearing and percen-
tage of weight loss in comparison with saline-treated animals. Mea-
suring the withdrawal parameters, as the degree of physical
dependence, after injection of naloxone (4mg/kg) did not reveal any
inhibitory eﬀect for acute sumatriptan-treated animals (all animals
were dependent to morphine by chronic administration of morphine
during ﬁve days). On the other hand, this data showed that physical
dependence induced with naloxone injection was potentiated in the
animals which received sumatriptan (1mg/kg). Sumatriptan at 1mg/
kg increased the number of jumping, rearing and weight loss compared
to the group that only received morphine (P < 0.05). Acute injection
of sumatriptan at 0.01mg/kg had a worsening eﬀect on the number of
rearing in morphine-dependent mice (P < 0.05).
3.8. Evaluating the chronic administration of sumatriptan on the morphine-
induced dependence
Fig. 8 showed that chronic administration of sumatriptan did not
protect animals from the withdrawal signs evoked by naloxone injec-
tion in morphine-dependent mice. Behavioral signs of morphine with-
drawal like jumping, rearing and the percentage of weight loss showed
no statistically signiﬁcant diﬀerence in animals which were treated
with sumatriptan and morphine compared to the group that only re-
ceived morphine.
3.9. Measurement of the nitrite level
The results of nitrite level assay in mice hippocampi is depicted in
Fig. 9. Chronic treatment with sumatriptan with doses of 0.001, 0.01
and 0.1mg/kg signiﬁcantly increased the level of nitrite compared to
morphine- and saline-treated groups (P < 0.001). Alteration in the
nitrite level at 1mg/kg was not statistically signiﬁcant.
Although the chronic administration of sumatriptan increased the
nitrite level in mice hippocampi, acute treatment with sumatriptan
showed no diﬀerence in the quantiﬁcation of nitrite level compared to
the morphine-treated group.
4. Discussion
The results of the present study revealed that acute and chronic
administration of sumatriptan, a speciﬁc 5HT1B/1D receptor agonist,
could signiﬁcantly alleviate morphine-induced antinociceptive toler-
ance. To obtain a comprehensive understanding of the role of NO
pathway, NOS inhibitors were co-administered with sumatriptan; the
results showed that inhibition of NO synthase blocks the sumatriptan
eﬀects on antinociceptive tolerance in both acute and chronic admin-
istration of sumatriptan in morphine-dependent mice. Acute and
chronic treatment with sumatriptan did not show protective eﬀect
against withdrawal signs precipitated by naloxone challenge in mor-
phine-dependent animals. As there was no conclusive data about the
eﬀect of sumatriptan on the morphine dependence, we did not use NOS
inhibitors with sumatriptan in the section of dependence evaluation.
Furthermore, the assessment of the nitrite level, as an end product of
NO, in mice hippocampi revealed that the amount of NO increased in
chronic sumatriptan-treated mice, but no diﬀerence was observed in the
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Fig. 4. The eﬀect of acute administration of NOS inhibitors on the eﬀects of
sumatriptan (SUMA) in morphine (MOR)-induced antinociceptive tolerance.
NOS inhibitors including L-NAME, a non-speciﬁc NOS inhibitor, 7-NI, a speciﬁc
nNOS inhibitor, aminoguanidine (AMINO), a speciﬁc iNOS inhibitor, were in-
jected 45min before sumatriptan. ***P < 0.001 compared to morphine (MOR)
on the ﬁfth day. ### P < 0.001 compared to concomitant administration of
sumatriptan with morphine. Data are expressed as mean± S.E.M. (n= 8).
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Fig. 5. The eﬀect of chronic administration of sumatriptan (SUMA) on the
antinociceptive tolerance to morphine (MOR). Diﬀerent doses of sumatriptan
were injected 45min before every dose of morphine during ﬁve days.
***P < 0.001 compared to control group. ###P < 0.001 and ##P < 0.01
compared to morphine-treated group on the last day. Data are expressed as
mean ± S.E.M. (n= 8).
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Fig. 6. The eﬀect of chronic administration of NOS inhibitors on the eﬀects of
sumatriptan (SUMA) in morphine (MOR)-induced antinociceptive tolerance. L-
NAME (2mg/kg), aminoguanidine (AMINO; 50mg/kg), and 7-NI (15mg/kg)
were injected 45min before each dose of sumatriptan. Data are expressed as
mean ± S.E.M. (n= 8). **P < 0.01 and ***P < 0.001 compared to control
group. ###P < 0.001 in comparison to the morphine-treated group. @
P < 0.05 and @@P < 0.01 compared to the co-administration of SUMA
0.1mg/kg+MOR.
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level of nitrite in acute treatment with sumatriptan.
Morphine and other opioids are considered standard antinociceptive
treatment for decades (Mao et al., 1995). But prolonged exposure to
these drugs is limited due to the rapid development of tolerance and
dependence. Numerous molecular mechanisms have been suggested for
these undesirable eﬀects of morphine, including desensitization of μ-
opioid receptor via receptor internalization, uncoupling from G-protein,
up-regulation of cAMP pathway, activation of N-methyl D-aspartate
(NMDA) system, central neuroimmune activation and NOS activation
(Bailey and Connor, 2005; Ben-Eliyahu et al., 1992; Bian et al., 2012;
Dang and Christie, 2012; Deleo et al., 2004; DuPen et al., 2007; Koch
and Höllt, 2008; Kolesnikov et al., 1993; Koppert, 2007; Martini and
Whistler, 2007; Ossipov et al., 2004). A great body of evidence suggests
the NO pathway as a proven mechanism involved in morphine-induced
tolerance/dependence phenomena. Studies showed that NO has a dual
role in modulating the antinociceptive tolerance to morphine. For ex-
ample, co-administration of L-arginine, the precursor of NO accelerated
the morphine tolerance in some studies (Babey et al., 1994). The study
that has been done on the mechanism involved in morphine anti-
nociceptive eﬀect by Dambisya and Lee (1996) revealed that NO has an
important role in morphine tolerance/dependence phases and sug-
gested that increase in the level of NO attenuates morphine-induced
antinociceptive tolerance and physical dependence, while inhibition of
NOS accelerated these two phenomena. Another study performed by
Thorat et al. (1993) reported that inhibition of NOS might prevent the
development of morphine antinociceptive tolerance. Although there is
evidence of both preventive and exacerbating eﬀects for NO pathway in
previous studies, our ﬁndings on the role of NO in the development of
tolerance to morphine were in favor of studies which suggested that
increasing the level of NO has a protective eﬀect against morphine-
induced antinociceptive tolerance.
Critical role of opioids in pain management in clinical setting led to
performing many investigations on the eﬃcacy of diﬀerent agents to
reduce or prevent tolerance and dependence induced by morphine
N
um
be
r o
f r
ea
rin
g
0
20
40
60
80
#
#
**
B
Acute treatment of SUMA
N
um
be
r o
f j
um
pi
ng
Co
nt
ro
l
MO
R
SU
MA
 0.
00
1
SU
MA
 0.
01
SU
MA
 0.
1
SU
MA
 1
Acute treatment of SUMA
Co
nt
ro
l
MO
R
SU
MA
 0.
00
1
SU
MA
 0.
01
SU
MA
 0.
1
SU
MA
 1
Acute treatment of SUMA
Co
nt
ro
l
MO
R
SU
MA
 0.
00
1
SU
MA
 0.
01
SU
MA
 0.
1
SU
MA
 1
0
20
40
60
80
**
#
A
W
ei
gh
t l
os
s 
(%
)
-5
0
5
10
15
20
***
#
C
Fig. 7. The eﬀect of acute treatment with sumatriptan (SUMA) on morphine (MOR)-induced physical dependence. Animals received diﬀerent doses of sumatriptan
45min before the last injection of morphine (100mg/kg). Signs of drug cessation including A. number of jumping, B. number of rearing, and C. percentage of weight
loss were measured after naloxone injection (4mg/kg). Data are expressed as mean± S.E.M. (n= 8). **P < 0.05 and ***P < 0.001 compared to control group.
#P < 0.05 compared to morphine-treated group.
M. Hassanipour et al. European Journal of Pharmacology 835 (2018) 52–60
57
N
um
be
r o
f j
um
pi
ng
0
50
100
150
*
A
Chronic treatment of SUMA
N
um
be
r o
f r
ea
rin
g
0
10
20
30
40
50
*
B
W
ei
gh
t l
os
s 
(%
)
Co
ntr
ol
MO
R
SU
MA
 0.
00
1
SU
MA
 0.
01
SU
MA
 0.
1
SU
MA
 1
-5
0
5
10
15
* * *
C
Chronic treatment of SUMA
Co
ntr
ol
MO
R
SU
MA
 0.
00
1
SU
MA
 0.
01
SU
MA
 0.
1
SU
MA
 1
Chronic treatment of SUMA
Co
ntr
ol
MO
R
SU
MA
 0.
00
1
SU
MA
 0.
01
SU
MA
 0.
1
SU
MA
 1
Fig. 8. The results of the chronic treatment of sumatriptan (SUMA) on the physical dependence to morphine (MOR). Animals were treated with diﬀerent doses of
sumatriptan 45min before each dose of morphine three times daily for ﬁve days. A. number of jumping, B. number of rearing, and C. percentage of weight loss as
three parameters of withdrawal signs were measured after naloxone injection (4mg/kg). Data are expressed as mean± S.E.M. (n= 8). *P < 0.05 and
***P < 0.001 compared to control group.
Chronic (5 days)
N
itr
ite
 (µ
M
)
0
20
40
60
N
itr
ite
 (µ
M
)
0
20
40
60
*** ***
***
B
Acute
MO
R
SU
MA
 0.
00
1 +
 M
OR
SU
MA
 0.
01
 + 
MO
R
SU
MA
 0.
1 +
 M
OR
SU
MA
 1 
+ M
OR MO
R
SU
MA
 0.
00
1 +
 M
OR
SU
MA
 0.
01
 + 
MO
R
SU
MA
 0.
1 +
 M
OR
SU
MA
 1 
+ M
OR
A
Fig. 9. The eﬀect of the administration of sumatriptan (SUMA) on the nitrite level of mice hippocampi. A. Animals received a single injection of sumatriptan 45min
before the last dose of morphine (MOR). B. Sumatriptan was injected 45min before daily treatment of morphine three times a day for 5 days. Data are expressed as
mean ± S.E.M. (n= 8). **P < 0.01 and ***P < 0.001 compared to control group. #P < 0.05 and ##P < 0.01 compared to morphine-treated group.
M. Hassanipour et al. European Journal of Pharmacology 835 (2018) 52–60
58
(Hassanipour et al., 2016a; Mao et al., 1996).
Sumatriptan, a 5HT1B/1D receptor agonist, is commonly known for
managing migraine type headaches and their associated symptoms.
Recent studies revealed further protective eﬀects of sumatriptan besides
its migraine pain relief property. Previous study suggested that suma-
triptan has a neuroprotective eﬀect in focal cerebral ischemia via im-
provement of brain blood ﬂow in rats (Mies, 1998). Another in-
vestigation showed that chronic administration of sumatriptan
improves depression and obsessive-compulsive disorder (OCD) in drug-
resistant patients (Stern et al., 1998). Despite the previous studies about
the eﬀect of sumatriptan in migraine pain, we observed that suma-
triptan with administrated doses in the current study did not exert
antinociceptive property by itself (without morphine administration) in
mice. Interestingly, sumatriptan raised the latency time which was
decreased following 5-days treatment with morphine, that is, suma-
triptan prevents morphine-induced antinociceptive tolerance.
Anti-migraine properties of sumatriptan are due to multiple me-
chanisms including direct vasoconstriction of the smooth muscles of
dilated meningeal vessels, inhibition of the releasing the nociceptive
neurotransmitters, increasing cholinergic neurotransmission, inhibition
of the secretion of calcium gene-related peptide (CGRP) and modulation
of NO signaling pathway (Dechant and Clissold, 1992; Durham and
Russo, 1999; Ghelardini et al., 1997; Read and Parsons, 2000; Tepper
et al., 2002). A large body of evidence implicated NO pathway as a
major mechanism involved in pharmacological properties of suma-
triptan (Akerman et al., 2002; Stepień et al., 1999; Tepper et al., 2002).
In this study administration of NOS inhibitors including L-NAME (non-
speciﬁc NOS inhibitor), 7-nitroindazole (speciﬁc neuronal NOS in-
hibitor), and aminoguanidine (speciﬁc inducible NOS inhibitor) in-
hibited the eﬀect of acute and chronic administration of sumatriptan on
the antinociceptive tolerance. In addition, chronic treatment with su-
matriptan enhanced the nitrite level in mice hippocampi, but the acute
administration did not exhibit this pattern. We assume that the in-
hibitory eﬀect of acute administration of sumatriptan on anti-
nociceptive tolerance is due to other mechanisms or involvement of
other parts of brain, besides hippocampus, such as locus coeruleus,
prefrontal cortex and glial cells (Ammon et al., 2003; Andrade et al.,
1983; Rossetio et al., 1993; Song and Zhao, 2001).
We examined the eﬀectiveness of treatment with sumatriptan on
morphine physical dependence. The results revealed that acute ad-
ministration of sumatriptan could not attenuate naloxone-precipitated
opioids withdrawal signs. Furthermore, chronic treatment with suma-
triptan did not modify the parameters of withdrawal signs evoked by
naloxone challenge in morphine-dependent mice. Based on these data,
sumatriptan could not prevent or attenuate physical dependence caused
by prolonged exposure to opioids. This interesting ﬁnding indicated the
dissociation between morphine-induced tolerance and physical depen-
dence mechanisms. Pharmacological dissociation between tolerance to
and dependence on morphine has been illustrated in previous studies.
Aley and Levine (1997) demonstrated that administration of L-NAME
blocks the antinociceptive tolerance induced by repeated administra-
tion of μ-opioid agonist enkephalin but does not prevent the develop-
ment of dependence. Similarly, Gabra et al. (2008) demonstrated a
signiﬁcant decrease in morphine-induced antinociceptive tolerance via
protein kinase C (PKC) and protein kinase A (PKA) inhibitors pre-
treatment, but these agents failed to prevent the development of phy-
sical dependence.
More investigations are highly recommended in order to clarify the
role of sumatriptan, the exact molecular basis of these eﬀects on anti-
nociceptive tolerance and dependence, gene expression and protein
expression in diﬀerent brain areas, and investigating the possible im-
plication of sumatriptan in clinical setting.
5. Conclusion
Our study concluded that sumatriptan could attenuate
antinociceptive tolerance induced by chronic administration of mor-
phine. This prevention was not observed in dependence phase. The
results suggested that the role of sumatriptan on morphine eﬀects is
modulated at least in part via NO-dependent pathway.
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